JOHNSON & JOHNSON is 335.6x more valuable than AGIOS PHARMACEUTICALS, INC. by market capitalization ($573.98 B vs $1.71 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AGIO | JNJ |
|---|---|---|
| Market cap | $1.71 B | $573.98 B |
| US-listed rank | #2223 | #20 |
| Revenue (latest FY) | $54.03M | $94.19B |
| Net income (latest FY) | -$413.00M | $26.80B |
| Net margin | -764.4% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 1,268 | 984 |
JOHNSON & JOHNSON is 335.6x more valuable than AGIOS PHARMACEUTICALS, INC. by market capitalization ($573.98 B vs $1.71 B).
In their latest fiscal years, AGIOS PHARMACEUTICALS, INC. reported $54.03M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: AGIOS PHARMACEUTICALS, INC. and JOHNSON & JOHNSON, or browse the full rankings.